In healthy normotensive subjects age and blood pressure better predict subclinical vascular and cardiac organ damage than atherosclerosis biomarkers

References

• Shemisa K, Bhatt A, Cheeran D, et al. Novel biomarkers of subclinical cardiac dysfunction in the general population. Curr Heart Fail Rep. 2017;14:301–310.
   PubMedGoogle Scholar
• Wang J, Tan GJ, Han LN, et al. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14:135–150.
   PubMedGoogle Scholar
• Redberg RF, Vogel RA, Criqui MH, et al. 34th Bethesda conference: task force #3––what is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J Am Coll Cardiol. 2003;41:1886–1898.
   PubMedGoogle Scholar
• Marchesi E, Martignoni A, Tinelli C, et al. Plasminogen activator inhibitor-1 and carotid intima-media thickening in patients with newly detected primary hypertension. J Cardiovasc Risk. 1999;6:363–369.
   PubMedGoogle Scholar
• Kondo K, Kitagawa K, Nagai Y, et al. Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression. Atherosclerosis. 2005;179:155–160.
   PubMed Web of Science ®Google Scholar
• Tan J, Hua Q, Xing X, et al. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res. 2007;30:959–963.
   PubMed Web of Science ®Google Scholar
• Kousios A, Kouis P, Panayiotou AG. Matrix metalloproteinases and subclinical stherosclerosis in chronic kidney disease: a systematic review. Int J Nephrol. 2016;2016:9498013.
   PubMedGoogle Scholar
• Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3–9.
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587.
   PubMed Web of Science ®Google Scholar
• Sakata T, Mannami T, Baba S, et al. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Atherosclerosis. 2004;176:355–360.
   PubMed Web of Science ®Google Scholar
• Nishiwaki Y, Takebayashi T, Omae K, et al. Relationship between the blood coagulation-fibrinolysis system and the subclinical indicators of arteriosclerosis in a healthy male population. J Epidemiol. 2000;10:34–41.
   PubMedGoogle Scholar
• Thakore AH, Guo CY, Larson MG, et al. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am J Cardiol. 2007;99:1598–1602.
   PubMed Web of Science ®Google Scholar
• Romero JR, Vasan RS, Beiser AS, et al. Association of carotid artery atherosclerosis with circulating biomarkers of extracellular matrix remodeling: the Framingham Offspring Study. J Stroke Cerebrovasc Dis. 2008;17:412–417.
   PubMedGoogle Scholar
• Song C, Burgess S, Eicher JD, et al. Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. J Am Heart Assoc. 2017;6:e004918.
   PubMed Web of Science ®Google Scholar
• Dong ZM, Chapman SM, Brown AA, et al. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest. 1998;102:145–152.
   PubMed Web of Science ®Google Scholar
• Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol. 2012;302:F1351–F1361.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens. 2006;15:270–275.
   PubMed Web of Science ®Google Scholar
• Salgado JV, Souza FL, Salgado BJ. How to understand the association between cystatin C levels and cardiovascular disease: imbalance, counterbalance, or consequence? J Cardiol. 2013;62:331–335.
   PubMed Web of Science ®Google Scholar
• Modification of Diet in Renal D. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–772.
   PubMed Web of Science ®Google Scholar
• The Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010;31:2338–2350.
   PubMed Web of Science ®Google Scholar
• Maloberti A, Meani P, Vallerio P, et al. Annexin A5 in treated hypertensive patients and its association with target organ damage. J Hypertens. 2017;35:154–161.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613–618.
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–270.
   PubMed Web of Science ®Google Scholar
• Maloberti A, Meani P, Varrenti M, et al. Structural and Functional Abnormalities of Carotid Artery and Their Relation with EVA Phenomenon. High Blood Press Cardiovasc Prev. 2015;22:373–379.
   PubMedGoogle Scholar
• Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J. 2012;53:258–261.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491–495.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–2060.
   PubMed Web of Science ®Google Scholar
• Kormi I, Nieminen MT, Havulinna AS, et al. Matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 predict incident cardiovascular disease events and all-cause mortality in a population-based cohort. Eur J Prev Cardiolog. 2017;24:1136–1144.
   PubMed Web of Science ®Google Scholar
• Dıez J, Gonzalez A, Lopez B, et al. Mechanisms of disease: pathologic structural remodelling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med. 2005;2:209–216.
   PubMedGoogle Scholar
• Ekmekçi H, Güngör Öztürk Z, Ekmekçi OB, et al. Significance of vitronectin and PAI-1 activity levels in carotid artery disease: comparison of symptomatic and asymptomatic patients. Minerva Med. 2013;104:215–223.
   PubMed Web of Science ®Google Scholar
• Duivenvoorden R, Mani V, Woodward M, et al. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. JACC Cardiovasc Imaging. 2013;6:1087–1094.
   PubMed Web of Science ®Google Scholar
• Guardamagna O, Abello F, Saracco P, et al. Endothelial activation, inflammation and premature atherosclerosis in children with familial dyslipidemia. Atherosclerosis. 2009;207:471–475.
   PubMed Web of Science ®Google Scholar
• Csongrádi É, Káplár M, Nagy B, et al. Adipokines as atherothrombotic risk factors in obese subjects: Associations with haemostatic markers and common carotid wall thickness. Nutr Metab Cardiovasc Dis. 2017;27:571–580.
   PubMed Web of Science ®Google Scholar
• Zureik M, Beaudeux JL, Courbon D, et al. Serum tissue inhibitors of metalloproteinases 1 (TIMP-1) and carotid atherosclerosis and aortic arterial stiffness. J Hypertens. 2005;23:2263–2268.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Okura T, Liu J, et al. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 2003;26:895–899.
   PubMed Web of Science ®Google Scholar
• Huang R, Gu J, Cao Q, et al. The association between serum cystatin C and carotid intima-media thickness in metabolic syndrome patients with normal estimated glomerular filtration rate. Clin Chim Acta. 2015;448:170–173.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Nishino T, Obata Y, et al. Association between cystatin C and arteriosclerosis in the absence of chronic kidney disease. J Atheroscler Thromb. 2013;20:548–556.
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke. Atherosclerosis. 2010;213:311–318.
   PubMed Web of Science ®Google Scholar
• Vilmi-Kerälä T, Lauhio A, Tervahartiala T, et al. Subclinical inflammation associated with prolonged TIMP-1 upregulation and arterial stiffness after gestational diabetes mellitus: a hospital-based cohort study. Cardiovasc Diabetol. 2017;16:49.
   PubMed Web of Science ®Google Scholar
• Yamasaki F, Furuno T, Sato K, et al. Association between arterial stiffness and platelet activation. J Hum Hypertens. 2005;19:527–533.
   PubMed Web of Science ®Google Scholar
• Ozkok A, Akpinar TS, Tufan F, et al. Cystatin C is better than albuminuria as a predictor of pulse wave velocity in hypertensive patients. Clin Exp Hypertens. 2014;36:222–226.
   PubMed Web of Science ®Google Scholar
• Song SH, Kwak IS, Kim YJ, et al. Serum cystatin C is related to pulse wave velocity even in subjects with normal serum creatinine. Hypertens Res. 2008;31:1895–1902.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Iizuka T, Takahashi M, et al. Association between cardio-ankle vascular index and serum cystatin C levels in patients with cardiovascular risk factor. J Atheroscler Thromb. 2009;16:371–379.
   PubMed Web of Science ®Google Scholar
• Odaira M, Tomiyama H, Matsumoto C, et al. Association of serum cystatin C with pulse wave velocity, but not pressure wave reflection, in subjects with normal renal function or mild chronic kidney disease. Am J Hypertens. 2010;23:967–973.
   PubMed Web of Science ®Google Scholar
• Gidding SS, Palermo RA, DeLoach SS, et al. Associations of cardiac structure with obesity, blood pressure, inflammation, and insulin resistance in African-American adolescents. Pediatr Cardiol. 2014;35:307–314.
   PubMed Web of Science ®Google Scholar
• Ishikawa J, Kario K, Matsui Y, et al. Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy. Hypertens Res. 2005;28:995–1001.
   PubMed Web of Science ®Google Scholar
• de Faria AP, Ritter AM, Sabbatini AR, et al. Deregulation of soluble adhesion molecules in resistant hypertension and its role in cardiovascular remodeling. Circ J. 2016;80:1196–1201.
   PubMed Web of Science ®Google Scholar
• Masiha S, Sundström J, Lind L. Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women. J Hum Hypertens. 2013;27:13–17.
   PubMed Web of Science ®Google Scholar
• Moran A, Katz R, Jenny NS, et al. Left ventricular hypertrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis. 2008;52:839–848.
   PubMed Web of Science ®Google Scholar